Trial Profile
A 24-week prospective, open-label, multicenter study to evaluate the effect on seizure frequency, safety and tolerability of oxcarbazepine monotherapy in adult patients with partial seizures
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Dec 2012
Price :
$35
*
At a glance
- Drugs Oxcarbazepine (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- Sponsors Novartis
- 29 Nov 2007 Status changed from in progress to completed.
- 27 Nov 2006 Status change
- 27 Jul 2006 New trial record.